DaVita Settles Lawsuit for $55 Million

NEW YORK ( TheStreet) -- DaVita Inc. ( DVA) announced Tuesday it has settled a lawsuit over its use of an anemia medication for $55 million.

Filed 10 years ago in a federal court in Texas, the lawsuit was based on one person's claim that the dialysis service provider overused Epogen, an anemia drug.

In a news release about the settlement, The Denver-based company said it and its physicians did nothing wrong and "stand by" their anemia management practices.

DaVita added that a government investigation into the Epogen-overuse claims hasn't yielded government intervention or claims.

The company also said the settlement contains no admissions of liability by the company or its affiliated physicians.

"Nonetheless, agreements such as this one are sometimes in the best interest of shareholders," DaVita said in a news release.

DaVita shares closed Tuesday up 9 cents at $97.71. U.S. stock markets were closed Wednesday in observance of the July Fourth holiday.

This article was written by a staff member of TheStreet.

More from Stocks

Russia Hacking Issue Makes Cybersecurity Stocks Look Like a Great Buy

Russia Hacking Issue Makes Cybersecurity Stocks Look Like a Great Buy

Jim Cramer Reacts to Reports of Private Equity Interest in Arconic

Jim Cramer Reacts to Reports of Private Equity Interest in Arconic

Dow Rises Slightly, Netflix Trades Higher Ahead of Earnings

Dow Rises Slightly, Netflix Trades Higher Ahead of Earnings

Jim Cramer: Bank of America Is Ahead in Technology

Jim Cramer: Bank of America Is Ahead in Technology

Bank of America Up 2% on Earnings Beat, But Analysts See Even More Gains Ahead

Bank of America Up 2% on Earnings Beat, But Analysts See Even More Gains Ahead